Loading...

Full Client Integration With Intellify Will Improve Client Retention

Published
24 Sep 24
Updated
18 Jun 26
Views
41
18 Jun
US$13.21
AnalystConsensusTarget's Fair Value
US$12.60
4.8% overvalued intrinsic discount
Loading
1Y
1.2%
7D
0.3%

Author's Valuation

US$12.64.8% overvalued intrinsic discount

AnalystConsensusTarget Fair Value

Last Update 18 Jun 26

Fair value Increased 1.31%

CCRN: Buyout Premium And Margin Recovery Expectations Will Anchor Future Share Performance

Analysts have adjusted their price target for Cross Country Healthcare stock slightly higher to about $12.60, citing updated fair value estimates and a modestly higher assumed future P/E multiple, despite a recent downgrade in Street research.

What’s in the News for Cross Country Healthcare

  • Knox Lane LP agreed to acquire Cross Country Healthcare in an all cash transaction valued at about $437 million, with stockholders to receive $13.25 per share, pending approvals and closing conditions. [Source: M&A Transaction Announcement]
  • The acquisition terms indicate Cross Country Healthcare stock is priced at a premium of about 31% to the closing price on May 6, 2026, and 45% to the 90 day volume weighted average trading price for the period ended May 6, 2026. [Source: M&A Transaction Announcement]
  • Upon completion of the transaction, Cross Country Healthcare is expected to become a privately held company in Knox Lane’s portfolio and cease trading on the Nasdaq, while continuing to operate under the Cross Country Healthcare name and brand. [Source: M&A Transaction Announcement]
  • From January 1, 2026 to March 31, 2026, Cross Country Healthcare repurchased 657,653 shares for about $5.83 million, bringing total buybacks under the August 16, 2022 program to 7,090,888 shares for about $130.45 million. [Source: Buyback Tranche Update]
  • A special or extraordinary shareholders meeting is scheduled for July 16, 2026, which is expected to relate to the proposed Knox Lane acquisition and associated approvals. [Source: Special/Extraordinary Shareholders Meeting]

Valuation Changes for Cross Country Healthcare

  • Fair Value: Updated to $12.60 from $12.44, a small upward adjustment in the estimated share value for Cross Country Healthcare stock.
  • Discount Rate: Held essentially steady at 7.11%, indicating no material change in the assumed risk profile used in the valuation model.
  • Revenue Growth: Maintained at about 2.88%, reflecting a stable assumption for long term top line expansion in the model.
  • Net Profit Margin: Kept broadly unchanged at about 104.29%, indicating no meaningful shift in the long term profitability assumption embedded in forecasts.
  • Future P/E: Adjusted slightly higher to about 42.18x from 41.64x, implying a modestly higher valuation multiple applied to projected earnings.
1 viewusers have viewed this narrative update

Key Takeaways

  • Increased demand and strategic investments in Travel Nursing and Physician Staffing segments drive significant revenue and growth potential.
  • Expansion of home care and technology integrations enhances margins and client retention, supporting long-term financial stability and growth.
  • Cross Country Healthcare faces significant revenue and margin pressure due to competitive compensation, market bill rate discrepancies, and delayed new deal revenues, impacting future profitability.

Catalysts

About Cross Country Healthcare
    Provides talent management and other consultative services for healthcare clients in the United States.
What are the underlying business or industry changes driving this perspective?
  • Cross Country Healthcare has seen an approximately 20% increase in orders in the Travel Nursing & Allied segment for the fourth quarter, indicating a potential inflection point and future volume growth, which may positively impact revenue.
  • The home care staffing segment is projected to grow in the mid-teens year-over-year in the fourth quarter and continues to expand its PACE programs nationwide, boosting revenue growth and potentially improving net margins due to a higher margin profile.
  • The Physician Staffing segment is experiencing strong demand, with expected low to mid-single-digit sequential revenue growth in the fourth quarter, facilitated by improved operating leverage and cost management, which should enhance both revenue and contribution income.
  • The company’s technology platform, Intellify, is expected to fully integrate all clients by the end of the year, which is anticipated to increase spend under management and drive revenue growth through improved margin contracts and client retention.
  • Cross Country Healthcare is focusing on capital allocation for potential M&A opportunities and strategic investments in technology, which could further expand the portfolio and enhance earnings growth while maintaining a strong balance sheet with no outstanding debt.
Cross Country Healthcare Earnings and Revenue Growth

Cross Country Healthcare Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming Cross Country Healthcare's revenue will grow by 2.9% annually over the next 3 years.
  • Analysts assume that profit margins will increase from -9.8% today to 1.0% in 3 years time.
  • Analysts expect earnings to reach $11.4 million (and earnings per share of $0.36) by about June 2029, up from -$98.6 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $14.8 million in earnings, and the most bearish expecting $10.1 million.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 42.3x on those 2029 earnings, up from -4.1x today. This future PE is greater than the current PE for the US Healthcare industry at 23.2x.
  • Analysts expect the number of shares outstanding to decline by 1.31% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 7.11%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • Cross Country Healthcare faces gross margin pressures due to competitive compensation packages in the Travel Nursing and Allied markets, impacting its profitability and ability to normalize margins in the near term. This could affect net margins negatively.
  • The company's revenue in the third quarter of 2024 was down 7% sequentially and 29% year-over-year, primarily due to expected declines in Travel Nursing and Allied. This potential continuing decline poses a risk to overall revenue growth.
  • Over 50% of job orders are not at market bill rates, which could limit Cross Country Healthcare's ability to increase production and fill assignments, potentially impacting revenue growth and overall earnings.
  • Despite expectations of growth, the Physician Staffing segment might face capacity limits and increased costs if additional resources are needed to sustain growth, impacting net margins.
  • While the company is focusing on M&A opportunities, the longer decision-making cycles at hospitals for MSP and VMS contracts could delay potential revenue from new deals, affecting revenue projections and net margins.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of $12.6 for Cross Country Healthcare based on their expectations of its future earnings growth, profit margins and other risk factors.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $13.25, and the most bearish reporting a price target of just $10.0.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.1 billion, earnings will come to $11.4 million, and it would be trading on a PE ratio of 42.3x, assuming you use a discount rate of 7.1%.
  • Given the current share price of $13.17, the analyst price target of $12.6 is 4.5% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Cross Country Healthcare?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives